source
- Moderna CEO Bancel optimistic after Phase 3 success of mRNA melanoma vaccine intismeranModerna chief executive Stéphane Bancel said the company will move quickly to obtain FDA approval for its experimental melanoma therapy intismeran after a Phase 3 trial showed positive results. Th…
- Tango Therapeutics reports 82% response rate for PRMT5 inhibitor combo in pancreatic cancer trialTango Therapeutics announced a 14% reduction in its workforce while also presenting new data on its PRMT5 inhibitor combined with Revolution Medicines’ RAS(ON) inhibitor Rasonque at the ESMO 2026 m…